Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vaccine platform technologies and national security

Vaccine platform technologies and national security Khalil Journal of the Egyptian Public Health Association (2021) 96:10 Journal of the Egyptian https://doi.org/10.1186/s42506-021-00070-5 Public Health Association LETTER TO THE EDITOR Open Access Vaccine platform technologies and national security 1,2 Mohamed K. M. Khalil The risk of global emerging infectious diseases or bioter- and preparedness to be undertaken in a more reasonable rorism will remain an important threat to the national timeframe than is possible before or during a pandemic. security of every country. Coordinated preparedness and Pandemic is not only a threat to an individual country response planning across all levels and agencies is an es- or region. Accordingly, a global movement for technol- sential strategy in combating cross-border emerging in- ogy transfer guided by the WHO or Gavi (Global Alli- fectious diseases or threats. The COVID-19 pandemic ance for Vaccines and Immunization) is needed to showed more than ever that developing countries can be ensure global preparedness and efficient response to an left behind during the times of need, as political power upcoming pandemic. Regional vaccine technology cen- to access and purchase vaccines and pandemic medica- ters may be part of the plan towards a global equal ac- tions was a crucial factor in the medical cess to vaccines. countermeasures. Abbreviations Vaccines are not developed in pharmaceutical com- COVID-19: Coronavirus disease 2019; WHO: World Health Organization; panies but in universities and research centers in devel- Gavi: Vaccine Alliance—Global Alliance for Vaccines and Immunization oped countries [1]. This will keep the majority of Acknowledgements developing countries away from the advanced technol- Not applicable ogy of vaccine development like vaccine platforms [2]. Platform vaccine technologies have been developed Author’s contributions that could make it possible to shorten the time needed The author declares that he is the single author of this manuscript. The author read and approved the final manuscript. to respond to an emerging infectious disease. Although there is no sharp definition of what constitutes a plat- Funding form, simply it is a spectrum of technologies that can Not funded. rapidly produce multiple vaccines from a single pluripo- Availability of data and materials tent underlying system or infrastructure [3, 4]. Not applicable. Vaccine platform technology is only an example of how scientific achievements in advanced countries can Declarations enhance rapid response to emerging infectious disease Ethics approval and consent to participate threats. Knowledge and technology transfer can bridge Not applicable. the gap to a certain extent between developed and devel- oping countries. However, the localization of advanced Consent for publication vaccine technology needs more than direct investments Not applicable. and strategic partnerships with the leading pharmaceut- Competing interests ical companies and research centers. A visionary political The author declares that he has no competing interest.. commitment to build national expertise in vaccine devel- opment is needed. It would allow difficult negotiations Received: 10 March 2021 Accepted: 3 April 2021 References Correspondence: statkhl@hotmail.com 1. Crager SE. Improving global access to new vaccines: intellectual property, Research and Development, Cairo, Egypt technology transfer, and regulatory pathways. Am J Public Health. 2014; Research and Development, Cairo, Egypt 104(11):11. © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Khalil Journal of the Egyptian Public Health Association (2021) 96:10 Page 2 of 2 2. Charlton Hume HK, Lua LHL. Platform technologies for modern vaccine manufacturing. Vaccine. 2017;35(35 Pt A):4480–5. https://doi.org/10.1016/j.va ccine.2017.02.069. 3. Adalja AA, Watson M, Cicero A, Inglesby T. Vaccine platform technologies: a potent tool for emerging infectious disease vaccine development. Health Secur. 2020;18(1):59–60. https://doi.org/10.1089/hs.2019.0148 4. Frederiksen LSF, Zhang Y, Foged C, Thakur A. The long road toward COVID- 19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol. 2020;11:1817. https://doi.org/10.3389/fimmu.2020. Publisher’sNote Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the Egyptian Public Health Association Springer Journals

Vaccine platform technologies and national security

Loading next page...
 
/lp/springer-journals/vaccine-platform-technologies-and-national-security-l1w5kvkya0
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
eISSN
2090-262X
DOI
10.1186/s42506-021-00070-5
Publisher site
See Article on Publisher Site

Abstract

Khalil Journal of the Egyptian Public Health Association (2021) 96:10 Journal of the Egyptian https://doi.org/10.1186/s42506-021-00070-5 Public Health Association LETTER TO THE EDITOR Open Access Vaccine platform technologies and national security 1,2 Mohamed K. M. Khalil The risk of global emerging infectious diseases or bioter- and preparedness to be undertaken in a more reasonable rorism will remain an important threat to the national timeframe than is possible before or during a pandemic. security of every country. Coordinated preparedness and Pandemic is not only a threat to an individual country response planning across all levels and agencies is an es- or region. Accordingly, a global movement for technol- sential strategy in combating cross-border emerging in- ogy transfer guided by the WHO or Gavi (Global Alli- fectious diseases or threats. The COVID-19 pandemic ance for Vaccines and Immunization) is needed to showed more than ever that developing countries can be ensure global preparedness and efficient response to an left behind during the times of need, as political power upcoming pandemic. Regional vaccine technology cen- to access and purchase vaccines and pandemic medica- ters may be part of the plan towards a global equal ac- tions was a crucial factor in the medical cess to vaccines. countermeasures. Abbreviations Vaccines are not developed in pharmaceutical com- COVID-19: Coronavirus disease 2019; WHO: World Health Organization; panies but in universities and research centers in devel- Gavi: Vaccine Alliance—Global Alliance for Vaccines and Immunization oped countries [1]. This will keep the majority of Acknowledgements developing countries away from the advanced technol- Not applicable ogy of vaccine development like vaccine platforms [2]. Platform vaccine technologies have been developed Author’s contributions that could make it possible to shorten the time needed The author declares that he is the single author of this manuscript. The author read and approved the final manuscript. to respond to an emerging infectious disease. Although there is no sharp definition of what constitutes a plat- Funding form, simply it is a spectrum of technologies that can Not funded. rapidly produce multiple vaccines from a single pluripo- Availability of data and materials tent underlying system or infrastructure [3, 4]. Not applicable. Vaccine platform technology is only an example of how scientific achievements in advanced countries can Declarations enhance rapid response to emerging infectious disease Ethics approval and consent to participate threats. Knowledge and technology transfer can bridge Not applicable. the gap to a certain extent between developed and devel- oping countries. However, the localization of advanced Consent for publication vaccine technology needs more than direct investments Not applicable. and strategic partnerships with the leading pharmaceut- Competing interests ical companies and research centers. A visionary political The author declares that he has no competing interest.. commitment to build national expertise in vaccine devel- opment is needed. It would allow difficult negotiations Received: 10 March 2021 Accepted: 3 April 2021 References Correspondence: statkhl@hotmail.com 1. Crager SE. Improving global access to new vaccines: intellectual property, Research and Development, Cairo, Egypt technology transfer, and regulatory pathways. Am J Public Health. 2014; Research and Development, Cairo, Egypt 104(11):11. © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Khalil Journal of the Egyptian Public Health Association (2021) 96:10 Page 2 of 2 2. Charlton Hume HK, Lua LHL. Platform technologies for modern vaccine manufacturing. Vaccine. 2017;35(35 Pt A):4480–5. https://doi.org/10.1016/j.va ccine.2017.02.069. 3. Adalja AA, Watson M, Cicero A, Inglesby T. Vaccine platform technologies: a potent tool for emerging infectious disease vaccine development. Health Secur. 2020;18(1):59–60. https://doi.org/10.1089/hs.2019.0148 4. Frederiksen LSF, Zhang Y, Foged C, Thakur A. The long road toward COVID- 19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol. 2020;11:1817. https://doi.org/10.3389/fimmu.2020. Publisher’sNote Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Journal

Journal of the Egyptian Public Health AssociationSpringer Journals

Published: Apr 20, 2021

There are no references for this article.